Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ONEFD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Promiximab-DUBA
|
|||||
| Synonyms |
Promiximab duocarmycin; Promiximab DUBA
Click to Show/Hide
|
|||||
| Organization |
West China Hospital
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Small cell lung cancer [ICD11:2C25]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
2.04
|
|||||
| Structure |
|
|||||
| Antibody Name |
Promiximab
|
Antibody Info | ||||
| Antigen Name |
Neural cell adhesion molecule 1 (NCAM1)
|
Antigen Info | ||||
| Payload Name |
seco-DUBA
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mal-Val-Cit-PABA-Cyclization spacer
|
Linker Info | ||||
| Conjugate Type |
Promiximab-DUBA conjugates were prepared via reduced interchain disulfides.
|
|||||
| Combination Type |
DUBA
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.